Suppr超能文献

骨质疏松症预防与治疗的最新进展

Recent advances in prophylactics and treatment of osteoporosis.

作者信息

Szamatowicz Marian, Szamatowicz Jacek

机构信息

Department of Medical Sciences Faculty of Health Sciences, Lomza State University of Applied Sciences Lomza, Poland.

Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Bialystok, Poland.

出版信息

Prz Menopauzalny. 2022 Jun;21(2):133-137. doi: 10.5114/pm.2022.116646. Epub 2022 Jun 20.

Abstract

Recently, a dramatic increase in the average life expectancy has been noted, regarded as the one of the greatest achievements of the last decades, but in consequence osteoporosis affects millions of people all over the world. Currently osteoporosis is defined as a skeletal disorder characterized by compromised bone strength which leads to an increased risk of fractures. The most commonly used tool to evaluate the 10-year risk of fractures is the fracture risk assessment tool validated in many independent cohorts. Osteoporosis itself has no symptoms, but fractures are common symptoms of osteoporosis which can result in disability and mortality. Hence, osteoporosis is called a silent epidemic as well as a silent killer. The best way to assess patients with osteoporosis is by using the most widely employed techniques - dual-energy X-ray absorptiometry or quantitative computed tomography. There are a lot of precisely documented risk factors of osteoporosis - e.g. cigarette smoking, alcohol use, getting little or no exercise, being small-framed or thin, a diet low in foods containing calcium and vitamin D - and their limitation or elimination is the best way for prophylactics of this dangerous disease. Some other risk factors such as age and sex of patients should not be omitted in the decision making process. In the literature there are numerous therapeutic proposals and different guidelines. In this review we present the recent advances in the prophylactics and treatment of osteoporosis.

摘要

最近,人们注意到平均预期寿命急剧增加,这被视为过去几十年最伟大的成就之一,但结果是骨质疏松症影响着全世界数百万人。目前,骨质疏松症被定义为一种以骨强度受损为特征的骨骼疾病,这会导致骨折风险增加。评估10年骨折风险最常用的工具是在许多独立队列中得到验证的骨折风险评估工具。骨质疏松症本身没有症状,但骨折是骨质疏松症的常见症状,可能导致残疾和死亡。因此,骨质疏松症被称为无声的流行病和无声的杀手。评估骨质疏松症患者的最佳方法是使用最广泛应用的技术——双能X线吸收法或定量计算机断层扫描。骨质疏松症有许多记录精确的风险因素,例如吸烟、饮酒、很少或不运动、身材矮小或消瘦、富含钙和维生素D的食物摄入不足的饮食,而限制或消除这些因素是预防这种危险疾病的最佳方法。在决策过程中,一些其他风险因素,如患者的年龄和性别也不应被忽视。文献中有众多的治疗建议和不同的指南。在这篇综述中,我们介绍了骨质疏松症预防和治疗方面的最新进展。

相似文献

1
Recent advances in prophylactics and treatment of osteoporosis.骨质疏松症预防与治疗的最新进展
Prz Menopauzalny. 2022 Jun;21(2):133-137. doi: 10.5114/pm.2022.116646. Epub 2022 Jun 20.
3
7
Osteoporosis.骨质疏松症
Clin Orthop Relat Res. 2000 Mar(372):139-50. doi: 10.1097/00003086-200003000-00016.
8
Epidemiology, etiology, and diagnosis of osteoporosis.骨质疏松症的流行病学、病因学及诊断
Am J Obstet Gynecol. 2006 Feb;194(2 Suppl):S3-11. doi: 10.1016/j.ajog.2005.08.047.

本文引用的文献

1
Abaloparatide: A review of preclinical and clinical studies.阿巴洛肽:临床前和临床研究综述。
Eur J Pharmacol. 2021 Oct 15;909:174409. doi: 10.1016/j.ejphar.2021.174409. Epub 2021 Aug 5.
2
Cardiovascular Safety and Sclerostin Inhibition.心血管安全性与硬骨素抑制
J Clin Endocrinol Metab. 2021 Jun 16;106(7):1845-1853. doi: 10.1210/clinem/dgab193.
6
Choosing the approach treatment strategy for osteoporosis in men.选择男性骨质疏松症的治疗策略
Expert Opin Pharmacother. 2020 Jun;21(9):993-995. doi: 10.1080/14656566.2020.1743266. Epub 2020 Mar 17.
9
State of the art in osteoporosis risk assessment and treatment.骨质疏松风险评估与治疗的最新进展。
J Endocrinol Invest. 2019 Oct;42(10):1149-1164. doi: 10.1007/s40618-019-01041-6. Epub 2019 Apr 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验